| 12 | 0 | 24 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨吸碘率对老年Graves病(GD)患者131碘治疗后疾病转归的预测价值。方法 选取首次接受131碘治疗的120例老年GD患者，在治疗后3个月复查患者甲状腺功能均正常。收集对象临床资料，并测定131碘治疗后24 h吸碘率，根据24 h吸碘率分为吸碘率增高组(24 h吸碘率>50%,n=34)、吸碘率正常组(24 h吸碘率30%～50%,n=48)和吸碘率减低组(24 h吸碘率<30%,n=38);所有患者随访1年，比较3组一般资料、疾病转归结局及甲状腺指标水平，采用Pearson相关分析探讨24 h吸碘率与甲状腺指标的关系。结果 吸碘率增高组复发率高于吸碘率正常组、吸碘率减低组，早发性甲状腺功能减低(甲减)发生率低于吸碘率正常组、吸碘率减低组，差异显著(均P<0.05);吸碘率正常组临床治愈率显著高于吸碘率减低组(P<0.05);3组临床治愈率、复发率、早发性甲减发生率比较差异有统计学意义(均P<0.05)。吸碘率增高组血清游离三碘甲状腺原氨酸(FT3)、三碘甲状腺原氨酸(TT3)、游离甲状腺素(FT4)、甲状腺素(TT4)水平较吸碘率正常组、吸碘率减低组高，血清促甲状腺激素(TSH)水平较吸碘率正常组、吸碘率减低组低，差异显著(均P<0.05)。3组血清FT3、TT3、FT4、TT4、TSH水平比较差异均有统计学意义(均P<0.05)。24 h吸碘率与血清FT3、TT3、FT4、TT4水平均呈正相关，与血清TSH水平呈负相关(P<0.001)。结论 131碘治疗后3个月对老年GD患者24 h吸碘率进行复查，能够有效预测患者治疗后早发性甲减和甲状腺功能亢进(甲亢)复发的发生风险，且24 h吸碘率与患者治疗后甲状腺指标水平之间密切相关。
Abstract：1 Wiersinga WM,Poppe KG,Effraimidis G.Hyperthyroidism:aetiology,pathogenesis,diagnosis,management,complications,and prognosis[J].Lancet Diabetes Endocrinol,2023;11(4):282-98.
2 Antonelli A,Fallahi P,Elia G,et al.Graves' disease:clinical manifestations,immune pathogenesis(cytokines and chemokines) and therapy[J].Best Pract Res Clin Endocrinol Metab,2020;34(1):101388.
3 Antonelli A,Ferrari SM,Ragusa F,et al.Graves' disease:epidemiology,genetic and environmental risk factors and viruses[J].Best Pract Res Clin Endocrinol Metab,2020;34(1):101387.
4 徐怡，彭松夏，秦丽，等.老年Graves病合并甲状腺功能亢进性心脏病患者肝功能与心功能的相关性[J].中国老年学杂志，2022;42(4):785-8.
5 Piccardo A,Ugolini M,Altrinetti V,et al.Radioiodine therapy of Graves' disease[J].Q J Nucl Med Mol Imag,2021;65(2):132-7.
6 Lane LC,Cheetham TD,Perros P,et al.New therapeutic horizons for graves' hyperthyroidism[J].Endocr Rev,2020;41(6):873-84.
7 王静.基于碘131分析仪的碘吸收率试验研究[J].粘接，2022;49(2):154-6.
8 中华医学会核医学分会.131I治疗格雷夫斯甲亢指南(2021版)[J].中华核医学与分子影像杂志，2021;41(4):242-53.
9 Hughes K,Eastman C.Thyroid disease:long-term management of hyperthyroidism and hypothyroidism[J].Aust J Gen Pract,2021;50(1-2):36-42.
10 林雪，范毅斌.TgAb与TpoAb检验在甲状腺功能相关疾病诊断中的应用价值[J].保健医学研究与实践，2023;20(S2):86-8.
11 Huang Y,Xu Y,Xu M,et al.Application of oral inorganic iodine in the treatment of Graves' disease[J].Front Endocrinol(Lausanne),2023;14(1):1150036.
12 Cho YY,Kim B,Choi D,et al.Graves' disease,its treatments,and the risk of atrial fibrillation:a Korean population-based study[J].Front Endocrinol(Lausanne),2022;13:1032764.
13 谢培林，徐聂，黄露萍.Graves甲亢患者131I治疗后甲减发生情况及与血清TGAb、TPOAb的关系[J].分子诊断与治疗杂志，2024;16(7):1303-6.
14 Zhu M,Zhao L,Lu X.Direct labeling of gold nanoparticles with iodine-131 for tumor radionuclide therapy[J].Int J Nanomed,2024;19(1):11805-18.
15 Tamura M,Nakada K,Iwanaga H,et al.Effect of previous administration of potassium iodine and different durations of low iodine diets for radioiodine therapy on the treatment of Graves' disease in iodine-rich areas[J].Eur J Nucl Med Mol Imaging,2024;51(4):1060-9.
16 Yu F,Zhang R,Zhang G,et al.Predictive value of a thyroid-absorbed dose with a shorter effective half-life on efficacy in graves disease patients receiving Iodine-131 therapy[J].Med Sci Monit,2021;27(1):e928796.
17 Mikura K,Yoshimura Noh J,Watanabe N,et al.Radioiodine uptake after monotherapy with potassium iodide in patients with Graves' disease[J].Endocr J,2023;70(5):541-9.
18 Horn-Lodewyk J.Correlation of radioiodine doses for 6-hr and 24-hour iodine-131 thyroid uptake values for Graves' hyperthyroidism[J].Endocr J,2019;66(12):1047-52.
19 冯少仁，张青，黄清梅，等.甲状腺吸碘率对Graves甲亢患者抗甲状腺药物治疗后选择停药时机的价值[J].临床荟萃，2019;34(8):730-3.
20 Song Q,Fang Z,Wang S,et al.Correlation between TRAb and early onset hypothyroidism after 131I treatment for Graves' disease[J].Horm Metab Res,2024;56(11):779-84.
21 Hu RT,Liu DS,Li B.Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients[J].BMC Endocr Disord,2020;20(1):76.
22 Chai J,Zhang R,Zheng W,et al.Effect of lugol's solution on 131I therapy efficacy in Graves' disease[J].Clin Exp Med,2023;23(3):825-31.
基本信息:
中图分类号:R581.1
引用信息:
[1]柴立超,王晶,魏雁,等.吸碘率对老年Graves病患者~(131)碘治疗后疾病转归的预测价值[J].中国老年学杂志,2026,46(08):1421-1424.
基金信息:
邢台市重点研发计划自筹项目(2025ZC068)
2026-04-22
2026-04-22